Background: Antiepileptic drugs are routinely given after craniotomy. Though phenytoin (PHT) is still the most commonly used agent, levetiracetam (LEV) is increasingly administered for this purpose. This retrospective study compared the use of LEV and PHT as monotherapy prophylaxis following supratentorial neurosurgery.
METHODS A research patient database was used to identify the electronic medical records for nonepileptic patients who underwent supratentorial neurosurgery and had at least a 7-day follow-up at Brigham and Women's Hospital or Massachusetts General Hospital during a 6-year period (January 1999 -December 2004). Records for patients who underwent procedures for insertion of pressure measurement devices or external and internal ventricular drainage devices were excluded. Of the electronic medical records identified, those of patients who received monotherapy postoperatively with either LEV or PHT were noted. All records for patients who received LEV monotherapy were reviewed, and compared to a group of patients receiving PHT (2:1 vs LEV, consisting of every 10th patient on PHT during the study period). Data collected included demographics; etiology; occurrence of seizures at presentation, 1 week postoperation (early seizures), and 30 days postoperatively; incidence of epilepsy (recurrent unprovoked seizures in those patients followed at least 1 year); drug dosing; maximum PHT level during hospitalization; adverse drug events due to PHT or LEV; and continued use of either drug among patients followed for at least 1 year.
Summary statistics include medians with minimum and maximum values for continuous data and percentages for binary data. The Fisher exact test was used to compare groups in terms of proportions. The Wilcoxon rank sum test was used to compare groups for continuous data. The Cochran-Mantel-Haenszel test was used to compare LEV and PHT in terms of early seizures after controlling for the presence of primary brain tumor, and the Breslow-Day test was used to test homogeneity of strata. Group comparisons limited to those with primary brain tumor were also performed as supporting analyses. Potential imbalance due to patient age was controlled for similarly. Statistical tests were performed using the SAS system version 9.1.
RESULTS
There were 105 patients in the LEV monotherapy group and 210 in the PHT group. The two groups were similar with respect to most baseline demographics and disease characteristics (table 1) . However, the PHT group tended to be older and have longer follow-up, while there was a greater incidence of primary brain tumor in the LEV group. Prior to surgery, 33 treated with LEV (22 of whom had a primary brain tumor) had experienced a seizure, vs 45 treated with PHT (26 of whom had a primary brain tumor) (p ϭ 0.07 for all diagnoses combined and p ϭ 0.69 for the primary brain tumor subgroup). Within the first 7 postoperative days a seizure occurred in 1/105 patients (1.0%) who received LEV (diagnosis was primary brain tumor) vs 9/210 (4.3%) who received PHT (2 of whom had a primary brain tumor) (p ϭ 0.17 for all combined diagnoses and p ϭ 1.0 for primary brain tumor subgroup). By postoperative day 30, the proportion was 1.9% for patients who received LEV, compared with 5.2% for those who received PHT (p ϭ 0.23).
There was a slightly greater proportion of early postoperative seizures in PHT vs LEV groups overall (table 2), but there was a lower proportion of patients with primary brain tumor in the PHT group (table  1) . Among the 99 total patients with primary brain tumor, those on PHT had a higher proportion with early seizures (3.6% vs 2.3%); among the 216 patients without tumor, those on PHT also had a higher proportion with early seizures (4.6% vs 0%). A stratified analysis revealed that the relationship between drug and seizure after adjusting for tumor presence was not significant (p ϭ 0.11). Further, the test of homogeneity of strata showed that the relationship between drug and seizure was not significantly different across the two strata (p ϭ 0.20). A large proportion of the patients who had an early postoperative seizure (by day 7) had experienced a preoperative seizure as well (1/1 LEV, and 6/9 PHT). Overall, 0% of patients taking LEV and 1.8% of patients taking PHT without a preoperative seizure experienced an early postoperative seizure (p ϭ 0.56). Of the original patients, 42 in the LEV group and 117 in the PHT group were followed for at least 12 months (p ϭ 0.01). By 12 months, 26% treated with LEV vs 36% treated with PHT developed epilepsy (p ϭ 0.34 for all diagnoses, and p ϭ 0.74 for the primary brain tumor subgroup). Similar proportions of each epilepsy group had had a preoperative PHT doses ranged from 200 to 800 mg a day. The most frequent dose used was 300 mg (91 patients). LEV doses ranged from 500 mg to 3,000 mg a day, with the most frequent dose being 1,000 mg a day (65 patients). In the PHT group, 8/9 with early postoperative seizures had serum levels recorded; maximum levels during the admission ranged from 10 to 20 mcg/mL with a median of 13.5 mcg/mL; among those without such seizures, 180/201 had levels checked, and the maximum level for each patient ranged from 1 to 27 mcg/mL with a median across patients of 11.0 mcg/mL (p ϭ 0.15). The patient treated with LEV who had an early postoperative seizure was receiving 3,000 mg a day and had a diagnosis of glioblastoma multiforme. In the PHT group followed for at least 1 year, those who developed epilepsy had higher maximum PHT levels during the early postoperative period (median 13.0 vs 11.5; p ϭ 0.01). However, among those with no preoperative seizure there was no significant difference between those who did and did not develop epilepsy (median 12.0 vs 11.0; p ϭ 0.72).
ADR prompting a change in AED therapy during hospitalization occurred in 1 patient taking LEV (with a diagnosis of primary brain tumor receiving 1,000 mg a day) (1%), who had visual hallucinations, vs 38 PHT (18%) (p Ͻ 0.001). This difference was still highly significant in a stratified analysis controlling for age. Of the 38 patients taking PHT with ADRs, 14 had a diagnosis of primary brain tumor. Other diagnoses in the ADR group were metastatic tumor (2), meningioma (5), hemorrhage (7) , vascular malformation (5), trauma (3), and other (2) . PHT reactions consisted of rash (22) , fever (8), cytopenia (3), allergy (2), rhabdomyolysis (1), cognitive change (1), and tremors (1) . Within the PHT group, the median of the maximum level during hospitalization in patients with ADRs was 13.5 mcg/mL compared to 11.0 mcg/mL in those without ADRs (p ϭ 0.005). This relationship remained significant after adjusting for age (p ϭ 0.005). Of the patients with epilepsy followed for at least 12 months, a greater percentage of those in the LEV group (64%) than in the PHT group (26%) remained on their treatment (p ϭ 0.03).
DISCUSSION
In this retrospective study, LEV appears to be at least as effective as PHT in prophylaxis of early and late postoperative seizures. The 25% in- Table 2 Incidence of seizures and epilepsy depending on pathology LEV PHT
All patients 105 210
Seizure preoperative 33 45
Seizure early postoperative 1 9 Patients followed >12 mo 42 117
Developed epilepsy* 11 42
Infection overall 4 4 Infection followed >12 mo 4 1
Seizure preoperative 1 2
Seizure early postoperative 0 0
Epilepsy* 1 1
Primary brain tumor overall 43 56
Primary brain tumor followed >12 mo 11 44
Seizure preoperative 22 26 Seizure early postoperative 1 2
Epilepsy* 5 2 4
Metastatic tumor overall 12 28 Metastatic tumor followed >12 mo 4 1 3
Seizure preoperative 4 5
Seizure early postoperative 0 2 Epilepsy* 0 3
Meningioma overall 11 36
Meningioma followed >12 mo 4 3 0
Seizure preoperative 3 7
Epilepsy* 1 7
Hemorrhage overall 21 41
Hemorrhage followed >12 mo 11 18
Seizure preoperative 1 1
Seizure early postoperative 0 2
Epilepsy* 1 3
Vascular malformation overall 10 14 Vascular malformation followed >12 mo 7 4
Seizure preoperative 2 0
Seizure early postoperative 0 1
Epilepsy* 3 1
Trauma overall 2 1 3
Trauma followed >12 mo 1 2
Seizure preoperative 0 1
Epilepsy* 0 1
Other overall 2 1 8
Other followed >12 mo 0 5 cidence of preoperative seizures was similar to other studies. 16, 19 The higher incidence of preoperative seizures in the patients with primary brain tumors (48%) has also been previously demonstrated. 5 The finding of a combined 3% incidence of early seizures in patients receiving AED prophylaxis is similar to other studies. 4, 5, 12 The PHT group had a 4.5fold greater incidence (4%) of early postoperative seizures compared to the LEV group (0.95%). Although this was not statistically significant, a larger sample size could potentially reveal significant differences. A high proportion, 70%, of the patients who had an early postoperative seizure also had had a preoperative seizure, as noted in previous studies. 11, 19, 20 The proportions with early postoperative seizures in PHT and LEV were not significantly different after controlling for pathology.
Seizure preoperative
Early seizures may lead to ischemia, increased edema, increased intracranial pressure, and difficulty following the clinical examination in postoperative patients. A patient who presents with a seizure and requires craniotomy may therefore benefit from AED treatment regardless of the etiology. Early postoperative and preoperative seizures are associated with an increased risk of later developing epilepsy. 20 The incidence of epilepsy was much higher in our patients who had a preoperative seizure than in those who had not; the number of patients with early postoperative seizures was too small to analyze the relationship of this phenomenon to later epilepsy. There was no significant difference in PHT levels among those with early seizures and those without. The finding of higher early postoperative PHT levels in patients who later developed epilepsy than in those who did not was attributable to those who had experienced preoperative seizures, since having a preoperative seizure was associated with both later epilepsy and higher levels.
Compared to PHT, LEV was associated with significantly fewer early adverse reactions, a particularly attractive feature when an agent is being used prophylactically. The incidence of ADR requiring discontinuation was 18% for PHT, similar to other studies. 9 Those with such reactions had significantly higher levels than those without, even though most of the reported side effects were not those commonly regarded as dose-or level-related. Combined with the lack of effect of level on incidence of early seizures, it is reasonable to recommend target levels in the low therapeutic range for those treated prophylactically with PHT.
The extremely low ADR rate for LEV, 1%, likely reflects mainly the acute situation, as the most commonly reported side effect of behavioral change 21 may take time to emerge, and, in addition, behav-ioral side effects may be less well documented in a retrospective study; nevertheless, the retention rate of LEV, considered a combined measure of tolerability and efficacy, also showed LEV to be superior to PHT.
LEV has the additional advantage of lack of drugdrug interactions, particularly important in seriously ill patients who often require multiple medications, such as oncology patients, who have great potential for toxicity and interactions with chemotherapy and radiation therapy. Enzyme-inducing AEDs (e.g., PHT, CBZ, PB) increase the clearance of corticosteroids and reduce the clinical efficacy of some anticancer agents. [22] [23] [24] [25] [26] PHT is also associated with an increased risk of Stevens Johnson syndrome and other mucocutaneous reactions during cranial irradiation. 27 Compared to other AEDs studied for prophylaxis after craniotomy, LEV appears to have a low incidence of side effects, and a dose of 500 mg BID may be sufficient.
Limitations of this study include those intrinsic to a retrospective study, especially those conducted at tertiary referral centers. For example, details of dayto-day care such as the dates of late postoperative seizures, and onset and details of AED tapering schedules were frequently not recorded. The question of when to terminate AED prophylaxis cannot be addressed based on this study. However, others have found that three quarters of all seizures occurred within the first 3 months 28 and have recommended stopping prophylaxis after 6 months. A meta-analysis of controlled trials showed that PHT prevents early provoked seizures with an estimated relative risk of 0.42 in craniotomy. However, none of the AEDs studied reduced seizure frequency beyond the first week. 17 In general, prophylaxis is recommended in the first week postsurgery for brain tumors, severe head injury, when there is a preoperative seizure or high risk of seizure (abscess, meningioma, arteriovenous malformation), and when a single seizure might have disastrous consequences. 1 In other situations, such as after aneurysmal subarachnoid hemorrhage, there is considerable practice variation and no consensus guidelines. 8 Future studies are needed to replicate these findings in a prospective manner. Placebo-controlled trials in low risk patients where standard of care often involves providing AEDs without clear benefit will be helpful, although a large N will be needed to obtain reliable results. In addition, LEV is now available in an IV formation, offering a realistic alternative to PHT and other AEDs with IV formulations for patients unable to take medication orally. A larger study could also assess for any antiepileptogenic effect. 29, 30 LEV is associated with a low risk of seizures postoperatively, at least as low as PHT. Early adverse reactions requiring drug discontinuation were significantly lower with LEV than PHT and retention rate at 1 year significantly higher. Since the benefit of prophylaxis in many cases is unclear, a low risk medication such as LEV is a reasonable choice.
